Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Short term Debt (2017 - 2023)

Capricor Therapeutics (CAPR) has 7 years of Short term Debt data on record, last reported at $18628.0 in Q2 2023.

  • For Q2 2023, Short term Debt fell 80.21% year-over-year to $18628.0; the TTM value through Jun 2023 reached $18628.0, down 80.21%, while the annual FY2022 figure was $89234.0, 85.11% down from the prior year.
  • Short term Debt reached $18628.0 in Q2 2023 per CAPR's latest filing, roughly flat from $18716.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $599388.0 in Q4 2021 and bottomed at $18628.0 in Q2 2023.
  • Average Short term Debt over 3 years is $211300.7, with a median of $89234.0 recorded in 2022.
  • The widest YoY moves for Short term Debt: up 80.21% in 2023, down 96.74% in 2023.
  • A 3-year view of Short term Debt shows it stood at $599388.0 in 2021, then tumbled by 85.11% to $89234.0 in 2022, then plummeted by 79.12% to $18628.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $18628.0 in Q2 2023, $18716.0 in Q1 2023, and $89234.0 in Q4 2022.